Neoadjuvant Letrozole Plus Taselisib Versus Letrozole Plus Placebo in Postmenopausal Women with Oestrogen Receptor-Positive, HER2-negative, Early-Stage Breast Cancer (LORELEI): a Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial